Immunotherapy in Alzheimer's disease: Where do we stand? Where should we go?

Journal of Alzheimer's Disease

Volumn 19, Issue 2, 2010, Pages 405-421

  Von Bernhardi, Rommy ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Alzheimer's disease; Amyloid clearance; Amyloid ; Cognitive impairment; Glial cells; Immunization; Microglia; Neuroinflammation; Senile plaques

Indexed keywords

ADENOVIRUS VECTOR; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; DEXAMETHASONE; DNA VACCINE; DRUG CARRIER; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; PLACEBO; QS 21;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ALZHEIMER DISEASE; BIOACCUMULATION; BLOOD BRAIN BARRIER; CELL ACTIVATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

EID: 77049106319     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1248     Document Type: Review

References (192)

1. Qiu C, De Ronchi D, Fratiglioni L (2007) The epidemiology of the dementias: an update. Curr Opin Psychiatry 20, 380-385.
2. Selkoe D (2001) Alzheimer's disease: genes, proteins and therapy. Physiol Rev 81, 741-766.
3. Kukull WA, Bowen JD (2002) Dementia epidemiology. Med Clin North Am 86, 573-590.
4. Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548-556.
5. Akiyama H Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B,Wenk G,Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
6. Demarin V, Kes VB, Morovi S, Zavoreo I (2009) Evaluation of aging vs dementia by means of neurosonology. J Neurol Sci 283, 9-12.
7. Fratiglioni L, Qiu C (2009) Prevention of common neurodegenerative disorders in the elderly. Exp Gerontol 44, 46-50.
8. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68, 1902-1908.
9. Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL (2001) Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res 902, 277-281.
10. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age-and region-dependent alterations in Abetadegrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26, 645-654.
11. Braak H, Braak E, Bohl J (1993) Staging of Alzheimerrelated cortical destruction. Eur Neurol 33, 403-408.
12. Goedert M (1998) Neurofibrillary Pathology of Alzheimer's Disease and other taupathies. In Progress in Brain Research, Van Leeuwen FW, Salehi A, Giger RJ, Holtmaat AJGD, Verhagen J, eds. Elsevier, Amsterdam, vol 117, pp. 287-306.
13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
14. Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM (2008) Amyloidbeta dynamics correlate with neurological status in the injured human brain. Science 321, 1221-1224.
15. Bossy-Wetzel E, Scharzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10, S2-S9.
16. Cumming JL (2004) Alzheimer's disease. N Engl J Med 351, 56-67.
17. von Bernhardi R, Eugeńin J (2004) Microglia - astrocyte interaction in Alzheimer's disease: modulation of cell reactivity to Aβ. Brain Res 1025, 186-193.
18. Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's Disease. Neuron 44, 181-193
19. Raḿirez G, Rey S, von Bernhardi R (2008) Proinflammatory stimuli induce microglial cell-mediated APP-and Aβ-neurotoxicity in hippocampal cultures. J Alzheimers Dis 15, 45-59.
20. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
21. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G,Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in a model of Alzheimer's disease. Nature 408, 982-985.
22. Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloidbeta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11, 931-938.
23. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23, 29-33.
24. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM(2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901.
25. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG (2004) Peripheral treatment with enoxaparin, a lowmolecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24, 4181-4186.
26. Schenk D, Barbour R, DunnW, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S,Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
27. Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 93, 452-455.
28. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94, 4109-4112.
29. Vehmas AK, Borchelt DR, Price DL, McCarthy D, Willis-Karp M, Peper MJ, Rudow G, Luyinbazi J, Siew LT, Troncoso JC (2001) Beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/ PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol 20, 713-721.
30. Zamora E, Handisurva A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC (2006) Papillomavirus like particles are an effective platform for amyloidbeta immunization in rabbits and transgenic mice. J Immunol 177, 262-2670.
31. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N,Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 6, 916-919.
32. Youkin SG (2001) Amyloid beta vaccination: reduced plaques and improved cognition. Nat Med 7, 18-19.
33. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31, 175-193.
34. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B,Wisniewski T (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. AmJ Pathol 159, 439-447.
35. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48, 567-579.
36. Frenkel D, Dewachter I, Van Leuven F, Solomon B (2003) Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21, 1060-1065.
37. Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, Hutter-Paier B, Solomon B (2004) EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 24, 105-113.
38. Hara H, Monsonego A,Yuasa K, Adachi K, Xiao X,Takeda S, Takahashi K, Weiner HL, Tabira T (2004) Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis 6, 483-488.
39. Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Pavlovic J,Wollmer MA, Nitsch RM, Moelling K (2004) Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J Mol Med 82, 706-714
40. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99, 10837-10842.
41. McGeer PL, McGeer EG (2004) Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035, 101-104.
42. Strohmeyer R, Shen Y, Rogers J (2000) Detection of complement alternate pathway mRNA and proteins in the Alzheimer's disease brain. Neurobiol Aging 81, 7-18.
43. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P (1992) Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89, 10016-10020.
44. Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, Price JL (2005) Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord 19, 55-66.
45. Brazil MI, Chung H, Maxfield FR (2000) Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia. J Biol Chem 275, 16941-16947.
46. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Jonson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D (2005) Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's dis ease. J Neurosci 25, 9096-9101.
47. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL (2001) Vaccination with soluble Abeta oligomers generates toxicityneutralizing antibodies. J Neurochem 79, 595-605.
48. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloidbeta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7, 369-372.
49. DeMattos RB, Bales KR, Cummings DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98, 8850-8855.
50. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P,Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8, 1263-1269.
51. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformationselective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281, 4292-4299.
52. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, Mc-Gowan EM, Murphy MP, Golde TE (2006) Anti-Abeta42-and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116, 193-201.
53. Morgan D (2006) Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem Int 49, 190-194.
54. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM (2006). Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83, 374-384.
55. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease. J Neurosci 22, 6331-6335.
56. Hock C, Konietzko U, Papassotiropoulos A,Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM (2002) Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8, 1270-1275.
57. Bayer AJ, Bullock R, Jones RW,Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94-101.
58. Richartz E, Stransky E, Batra A, Simon P, Lewczuk P, Buchkremer G, Bartels M, Schott K (2005) Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? J Psychiatr Res 39, 535-543.
59. Sohn JH, So JO, Kim H, Nam EJ, Ha HJ, Kim YH, Mook-Jung I (2007) Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. Biochem Biophys Res Commun 361, 800-804.
60. Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9, 185-194.
61. Radaev S, Sun PD (2001) Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. Curr Opin Invest Drugs 6, 35-47.
62. Winkelhake JL, Kunicki TJ, Elcombe BM, Aster RH (1980) Effects of pH treatments and deglycosylation of rabbit immunoglobulin G on the binding of C1q. J Biol Chem 255, 2822-2828.
63. Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y (2007) Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. J Neurosci 26, 2458-2468.
64. Rebe S, SolomonB(2005) Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in Bv-2 cellular model. Am J Alzheimers Dis Other Demen 20, 303-313.
65. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D. (2006) Intracranial administration of deglycosylated C-terminalspecific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation 3, 11.
66. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D (2006) Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26, 5340-5346.
67. Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, Grimm J, Pons J, Morgan D (2008) Deglycosylated anti-Aβ antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol 3, 187-197.
68. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65, 1040-1048.
69. Bombois S, Maurage CA, Gompel M, Deramecourt V, Mackowiak-Cordoliani MA, Black RS, Lavielle R, Delacourte A, Pasquier F (2007) Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 64, 583-587.
70. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Sub acute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
71. Birmingham K, Frantz S (2002) Set back to Alzheimer vaccine studies. Nat Med 8, 199-200.
72. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo J-M (2005) AN1792 (QS21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
73. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
74. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9, 448-452.
75. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131.
76. Robinson SR, BishopGM,Lee HG,MünchG(2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25, 609-615.
77. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572.
78. Ferrer I, Boada Rovira M, Śanchez Guerra ML, Rey MJ, Costa-Jusśa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14, 11-20.
79. Patton RL, Kalback WM, Esh CL, Kokiohn TA, Van Vickle GD, Luers DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castano EM, Roher AE (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169, 1048-1063.
80. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299-3310.
81. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223.
82. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
83. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ,Wei X, FarlowM, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75, 1472-1474.
84. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S,Younkin L, Schiff R,Weksler ME(2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30, 1728-1736.
85. Foster JK, Verdile G, Bates KA, Martins RN (2009) Immunization in Alzheimer's disease: naïve hope or realistic clinical potential? Mol Psychiatry 14, 239-251.
86. Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, Steinitz M (2005) Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 26, 597-606.
87. Geylis V, Steinitz M (2006) Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 5, 33-39.
88. Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG (2006a) Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 24, 2275-2282.
89. Ghochikyan A, Petrushina I, Lees A, Vasilevko V, Movsesyan N, Karapetyan A, Agadjanyan MG, Cribbs DH (2006b) Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. DNA Cell Biol 25, 571-580.
90. Schenk D (2004) Hopes remain for an Alzheimer's vaccine. Nature 431, 398.
91. Atwood CS, Perry G, SmithMA(2003) Cerebral hemorrhage and amyloid-beta. Science 299, 1014.
92. Melnikova I (2007) Therapies for Alzheimer's disease. Nat Rev Drug Discov 6, 341-342.
93. Lichtlen P, Mohajeri MH (2007) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104, 859-874.
94. Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C (2007) Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 104, 15659-15664.
95. Mohajeri MH(2007) The underestimated potential of the immune system in prevention of Alzheimer's disease pathology. Bioessays 29, 927-932.
96. Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, Zeng J, Ehrhart J, Fernandez F, Morgan D, Giunta B, Town T, Tan J (2008) CD40L disruption enhances Aβ vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis 29, 336-353.
97. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382, 716-719.
98. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23, 3745-3751.
99. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D (2004) Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15, 11-20.
100. Akiyama H, McGeer PL (2004) Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 10, 117-118
101. DeWitt DA, Perry G, Cohen M, Doller C, Silver J (1998) Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 149, 329-340.
102. Alarćon R, Fuenzalida C, Santib́añez M, von Bernhardi R (2005) Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid. J Biol Chem 280, 30406-30415.
103. Streit WJ (2004) Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77, 1-8.
104. Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1, 14.
105. El Khoury J,Toft M, Hickman SE, Means TK,Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13, 432-438.
106. Rogers J, Strohmeyer R, Kovelowski CJ, Li R (2002) Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40, 260-269.
107. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA 104, 12849-12854.
108. Hoozemans JJ,Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJ, Eikelenboom P (2002) The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res 951, 218-226.
109. Floden AM, Combs CK (2006) Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci 26, 4644-4648.
110. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22, 7873-7878.
111. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 23, 8532-8538.
112. Frenkel D, Solomon B, Benhar I (2000) Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 106, 23-31.
113. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD (2003) CD36 mediates the innate host response to beta-amyloid. J Exp Med 197, 1657-1666.
114. Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, Lockett S, Dunlop NM, Wang JM (2006) Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem 281, 3651-3659.
115. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K (2005) LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 128, 1778-1789.
116. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502.
117. Fiala M, Lin J, Ringman J,Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G (2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 7, 221-232.
118. Malm TM, Koistinaho M, Pärepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 18, 134-142.
119. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14, 681-687.
120. Garcia-Alloza M, Ferrara BJ, Dodwell SA, Hickey GA, Hyman BT, Bacskai BJ (2007) A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol Dis 28, 286-292.
121. DeMattos RB, Bales KR, Cummings DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
122. Zlokovic BV (2002) Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. Adv Drug Deliv Rev 54, 1553-1559.
123. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
124. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
125. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457.
126. Vasilevko V, Xu F, Previti ML,Van Nostrand WE, Cribbs DH (2007) Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid-β in CNS of Tg-SwDI Transgenic Mice. J Neurosci 27, 13376-13383.
127. Frenkel D, Balass M, Katchalski-Katzir E, Solomon B (1999) High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J Neuroimmunol 95, 136-142.
128. Klyubin I,Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561.
129. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002). Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23, 2223-2226.
130. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
131. Simard AR, Rivest S (2006) Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry 11, 327-335.
132. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64, 743-753.
133. von Bernhardi R (2007) Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox Res 12, 215-232.
134. Rakover I, Arbel M, Solomon B (2007) Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 4, 392-402.
135. Servida F, Ravasi C, Puricelli M, Formentin EA, Dall'Ara P, Poli G (2007) Decrease in neuroinflammation after immunisation with synthetic prion peptides in an animal model of scrapie. Vet Res Commun 31 Suppl 1, 265-267.
136. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, Arendash GW(2006) Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 23, 351-361.
137. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW(2009) Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 34, 63-70.
138. Raḿirez G, Toro R, Döbeli H, von Bernhardi R (2005) Protection of rat primary hippocampal cultures from Aβ cytotoxicity by pro-inflammatory molecules is mediated by astrocytes. Neurobiol Dis 19, 243-254.
139. Di Filippo M, Sarchielli P, Picconi B, Calabresi P (2008) Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 29, 402-412.
140. Ryu JK, Tran KC, McLarnon JG (2007) Depletion of neutrophils reduces neuronal degeneration and inflammatory responses induced by quinolinic acid in vivo. Glia 55, 439-451.
141. Ji KA, Eu MY, Kang SH, Gwag BJ, Jou I, Joe EH (2008) Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia 56, 1039-1047.
142. Pan W, Yu C, Hsuchou H, Zhang Y, Kastin AJ (2008) Neuroinflammation facilitates LIF entry into brain: role of TNF. Am J Physiol Cell Physiol 294, C1436-1442.
143. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA (2006) Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 20, 426-433.
144. Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Schulze Topphoff U, Vogt J, Prozorovski T, Meier S, Osmanova V, Pohl E, Bechmann I, Nitsch R, Zipp F (2005) Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421-432.
145. Aktas O, Ullrich O, Infante-Duarte C, NitschR, Zipp F (2007) Neuronal damage in brain inflammation. Arch Neurol 64, 185-189.
146. Steinman L, Zamvil SS (2005) Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 26, 565-571.
147. Heppner FL, Gandy S, McLaurin J (2004) Current concepts and future prospects for Alzheimer disease vaccines. Alzheimer Dis Assoc Disord 18, 38-43.
148. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357, 169-175.
149. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I,Wall A, Ringheim A, Lngström B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856-2866.
150. Hoozemans JJ, Veerhuis R, Van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P, Scheper W(2005) The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 110, 165-172. (Pubitemid 41245205)
151. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W(2009) The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 174, 1241-1251.
152. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
153. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
154. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332.
155. Ǵomez-Isla T, Price JL, McKeel DWJr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16, 4491-4500.
156. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ (2009) Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72, 56-62.
157. Yuyama K,Yanagisawa K (2009) Late endocytic dysfunction as a putative cause of amyloid fibril formation in Alzheimer's disease. J Neurochem 109, 1250-1260.
158. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. JNeurosci 28, 8354-8860.
159. Lesńe S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
160. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
161. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE (2006b) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 20, 2576-2578.
162. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG (2007) Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric aß species in amyloid precursor protein transgenic mice. J Neurosci 27, 12721-21231
163. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
164. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7, 483-493.
165. Wolfe MS (2008) Selective amyloid-beta lowering agents. BMC Neurosci 9 Suppl 2, S4.
166. Wolfe MS (2008) Inhibition and modulation of gammasecretase for Alzheimer's disease. Neurotherapeutics 5, 391-398.
167. Rafii MS, Aisen PS (2009) Recent developments in Alzheimer's disease therapeutics. BMC Med 19, 7.
168. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905.
169. Pollack SJ, Lewis H (2005) Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Invest Drugs 6, 35-47.
170. Schwab C, Hosokawa M, McGeer PL (2004) Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188, 52-64.
171. Batra SK, Jain M,Wittel UA, Chauhan SC, Colcher D (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13, 603-608.
172. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR (2004) Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43, 6959-6967.
173. Fukuchi K, Accavitti-Loper MA, Kim HD, Tahara K, Cao Y, Lewis TL, Caughey RC, Kim H, Lalonde R (2006) Amelioration of amyloid load by anti-Aβ single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344, 79-86.
174. Solomon B, Frenkel D (2002) Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology. J Neural Transm Suppl 62, 321-325.
175. Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ (2005) Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expr Purif 42, 255-267.
176. Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D, He W (2003) A novel recombinant adenoassociated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14, 365-379.
177. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112, 415-422.
178. Frenkel D, Maron R, Burt DS, Weiner H (2005) Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115, 2423-2433.
179. Kim HD, Jin JJ, Maxwell JA, Fukuchi K (2007) Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 112, 30-38.
180. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446-452.
181. de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H (2007) Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 1097, 114-145.
182. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
183. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Lngström B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465.
184. Pauwels EK, Volterrani D, Mariani G (2009) Biomarkers for Alzheimer's disease. Drug News Perspect 22, 151-160.
185. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S (2009) Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 66, 632-637.
186. McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22, 799-809.
187. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66, 343-348.
188. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12, 1005-1015.
189. Cummings JL, Doody R, Clark C (2007) Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69, 1622-1634.
190. Pratic̀o D (2008) Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 1147, 70-78.
191. Streit WJ, Braak H, Xue QS, Bechmann I (2009) Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 118, 475-485.
192. McCarty MF (2006) Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses 67, 251-269.